ALN-PNP for MASLD and Healthy Adults
This study is testing an experimental drug called ALN-PNP. It's a "first-in-human" study, meaning it's the first time this drug is being given to people. The drug is not yet approved by health agencies like the FDA. The main goal is to see how safe ALN-PNP is and how well people tolerate it. Researchers will also look at potential side effects. You might be able to join if you are a healthy adult or an adult with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), especially if you have a specific gene variant. Some parts of the study focus on healthy adults, while others focus on those with MASLD. This study is currently recruiting up to 172 participants.
- Study design
- This is an interventional study with an unspecified phase, involving up to 172 participants. Participants will receive either ALN-PNP or a placebo (an inactive substance).
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for side effects for up to 337 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
At a glance
Conditions
NCT05648214
Where you'd take part
This study runs at 6 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Genoma Research Group, Inc
Miami, Floridano site contact published
Recruiting
Med Research of Florida, LLC
Miami, Floridano site contact published
Recruiting
Pioneer Research Solutions
Houston, Texasno site contact published
Recruiting
Tandem Clinical Research
Marrero, Louisianano site contact published
Recruiting
Velocity Clinical research
Los Angeles, Californiano site contact published
Recruiting
California Clinical Trials Medical Group
Glendale, Californiano site contact published
Completed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Up to Day 337
- Severity of TEAEsUp to Day 337